| 1 |
35324529 | Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. | 2022 Mar 23 |
2 |
| 2 |
34589994 | BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib. | 2021 Mar |
2 |
| 3 |
32093123 | Synergistic Anti-Tumour Effect of Syk Inhibitor and Olaparib in Squamous Cell Carcinoma: Roles of Syk in EGFR Signalling and PARP1 Activation. | 2020 Feb 19 |
2 |
| 4 |
32936912 | Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models. | 2020 Nov 10 |
1 |
| 5 |
33070053 | Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). | 2020 Dec |
1 |
| 6 |
31382135 | Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. | 2019 Oct |
1 |
| 7 |
31438892 | Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer. | 2019 Aug 22 |
1 |
| 8 |
30407790 | Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation. | 2018 Nov 27 |
3 |
| 9 |
26422459 | Quantitative proteomics unveiled: Regulation of DNA double strand break repair by EGFR involves PARP1. | 2015 Sep |
1 |
| 10 |
23966292 | EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. | 2013 Oct 15 |
2 |